Phone: 501-603.1418
Office: ED II_6/134C
Email: skeisner@uams.edu
Education & Training
- 2009-2010 PGY2 Hematology/Oncology Residency, Texas Tech University Health Sciences Center School of Pharmacy/VA North Texas Healthcare System, Dallas, TX
- 2008-2009 PGY1 Pharmacy Practice Residency, Parkland Hospital, Dallas, TX
- 2008 Doctor of Pharmacy, UAMS College of Pharmacy, Little Rock, AR
- 2004 Bachelor of Arts in biology, Hendrix College, Conway, AR
Teaching Responsibilities
PHPR 7355 Drug-Induced Diseases
PHSC 7204 Molecular Biology and Biotechnology
PHPR 7304 Therapeutics III Oncology Module
Clinical Practice
Clinical Pharmacist (Infusion Clinic), UAMS Winthrop P. Rockefeller Cancer Institute
Memberships
Hematology/Oncology Pharmacy Association
Publications
Keisner SV. Cabazitaxel. Pharmacist’s Applications to Practice. Sept 14, 2017 [Online] Available at: www.hoparx.org/drug-updates-from-the-fda/cabazitaxel-jevtana-sanofi-aventis.
Casserly EA, Rogers SE, Keisner SV. Lack of interaction between enzalutamide and warfarin in a metastatic castration-resistant prostate cancer patient. J Oncol Pharm Pract. 2017 Jan;23(1):68-70. Epub 2016 Jul 9.
Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011;71(4):443-54.
Jean GW, Shah SR, Keisner SV, Ussery SM, Dowell JE. Risk of renal failure in cancer patients with bone metastasis receiving renally adjusted zoledronic acid. Support Care Cancer. 2012;20(1):87-93. Epub 2011 Jan 1.
Keisner SV, Jean GW, Ussery SM, Dowell JE, Shah SR. A retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced androgen-independent prostate cancer. Ann Pharmacother. 2010;44(10):1538-44. Epub 2010 Sep 14.